Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration
- 1 February 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 31 (2), 189-198
- https://doi.org/10.1097/cji.0b013e31815dc0e8
Abstract
The regulation of tolerance to self-proteins and the suppression of T-cell responses have in part been attributed to the activity of CD25+CD4+ T regulatory (Treg) cells. Further, Treg cells can inhibit the antitumor effectiveness of adoptive immunotherapy and active immunization approaches in preclinical models. In an effort to selectively eliminate Treg cells from human peripheral blood mononuclear cell to potentially bolster antitumor responses, we have evaluated the Treg-cell depleting capacity of the CD25-directed immunotoxin, RFT5-SMPT-dgA. In preclinical studies, incubation of human peripheral blood mononuclear cell with RFT5-SMPT-dgA mediated a partial reduction in the levels of CD25+, Foxp3-expressing CD4+ T cells in vitro. Administration of RFT5-SMPT-dgA to 6 patients with metastatic melanoma induced a transient but robust reduction in the number of CD25high CD4+ T cells in vivo (a 97.5% mean reduction at nadir; from 69.4±12.4 cells/μL to 1.7±0.3 cells/μL). The reduction in FOXP3+ CD4+ T-cell number was less comprehensive (a 71.3% mean reduction at nadir; from 66.6±16.5 cells/μL to 14.2±3.9 cells/μL). This resulted in the selective persistence of a stable number of CD25low/neg FOXP3+ CD4+ T cells in vivo. No objective antitumor responses were seen in any patient. Our results indicate that the CD25-directed, RFT5-SMPT-dgA immunotoxin can mediate a transient, partial reduction in Treg-cell frequency and number in vitro and in vivo and suggest that comprehensive eradication of human Treg cells in vivo may require the ability to target and eliminate FOXP3+ CD4+ T cells expressing both high and low levels of CD25.Keywords
This publication has 54 references indexed in Scilit:
- Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting ChemotherapyJournal of Immunotherapy, 2007
- Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitroInternational Journal of Cancer, 2007
- Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell developmentProceedings of the National Academy of Sciences of the United States of America, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJCI Insight, 2005
- Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantationTransplantation and Cellular Therapy, 2004
- Remission of Follicular Non-Hodgkin's Lymphoma with Denileukin Diftitox (ONTAK ® ) After Progression During Rituximab, CHOP and Fludarabine TherapyLeukemia & Lymphoma, 2003
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cellsEuropean Journal of Immunology, 1990
- A KINETIC ANALYSIS OF THE EFFECTS OF INTERLEUKIN-2 DIPHTHERIA TOXIN FUSION PROTEIN UPON ACTIVATED T CELLSTransplantation, 1990